Clinical Trial 42122

Tampa, FL 33613


Study Summary:

Study 42122 Flyer
Click image to enlarge

The Hope4MCI study is a global Phase 3 clinical trial to assess the efficacy and safety of low dose levetiracetam (AGB101) to slow the progression of symptoms associated with MCI and prevent or delay the onset of Alzheimer's dementia.  Participants will complete 3 screening visits which may include and MRI and amyloid PET - and will assigned to once a day AGB101 or placebo treatment for 18 months.  Participants will complete 7 clinic visits over 18 months.


Qualified Participants Must:

• Have recent memory changes or received a diagnosis of mild cognitive impairment (MCI)
• Be 55 - 85 years old
• Study partner able to attend screening and all major study visits


Qualified Participants May Receive:

Compensation for your time

Evaluation and testing of your memory, thinking skills, daily functioning, and behavior

Posittron Emission Tomography (PET) scan of your brain

MRI, Blood and urine tests

Low dose levetiracetam (AGB101) or a placebo


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.